Enrique Alvarez
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 46 | 2026 | 435 | 8.750 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 16 | 2026 | 66 | 3.920 |
Why?
| | Immunologic Factors | 9 | 2026 | 244 | 3.230 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 35 | 2.130 |
Why?
| | Natalizumab | 5 | 2023 | 30 | 2.070 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 24 | 1.990 |
Why?
| | Rituximab | 7 | 2025 | 208 | 1.830 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 829 | 1.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2025 | 992 | 0.970 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 36 | 0.940 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 9 | 0.940 |
Why?
| | Drug Substitution | 2 | 2025 | 62 | 0.920 |
Why?
| | Oligoclonal Bands | 3 | 2026 | 25 | 0.720 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 135 | 0.670 |
Why?
| | Serum Sickness | 1 | 2019 | 3 | 0.600 |
Why?
| | Magnetic Resonance Imaging | 12 | 2026 | 3926 | 0.570 |
Why?
| | Adult | 38 | 2026 | 41087 | 0.500 |
Why?
| | Medical Marijuana | 1 | 2018 | 120 | 0.490 |
Why?
| | Middle Aged | 37 | 2026 | 36619 | 0.480 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 135 | 0.470 |
Why?
| | Antigens, CD20 | 3 | 2025 | 34 | 0.460 |
Why?
| | Antibodies, Monoclonal | 5 | 2026 | 1512 | 0.460 |
Why?
| | Biomarkers | 6 | 2026 | 4340 | 0.460 |
Why?
| | Pregnancy Complications | 2 | 2018 | 609 | 0.460 |
Why?
| | Axons | 2 | 2014 | 205 | 0.450 |
Why?
| | Humans | 66 | 2026 | 146342 | 0.440 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.440 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 83 | 0.410 |
Why?
| | Female | 44 | 2026 | 79499 | 0.400 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1064 | 0.390 |
Why?
| | Anemia | 1 | 2015 | 190 | 0.380 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 15 | 0.380 |
Why?
| | Recurrence | 6 | 2024 | 1133 | 0.370 |
Why?
| | Male | 40 | 2026 | 73396 | 0.350 |
Why?
| | Brain | 9 | 2026 | 2991 | 0.320 |
Why?
| | Demyelinating Diseases | 4 | 2026 | 78 | 0.320 |
Why?
| | T-Lymphocytes | 3 | 2023 | 2012 | 0.290 |
Why?
| | Immunoglobulin G | 4 | 2026 | 901 | 0.290 |
Why?
| | Muscle, Skeletal | 6 | 2026 | 1818 | 0.270 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 11 | 0.270 |
Why?
| | Walking | 4 | 2023 | 546 | 0.260 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 170 | 0.260 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 481 | 0.260 |
Why?
| | Leukoencephalopathies | 1 | 2026 | 23 | 0.240 |
Why?
| | Neuroimaging | 2 | 2026 | 307 | 0.240 |
Why?
| | Fatigue | 3 | 2026 | 363 | 0.230 |
Why?
| | B-Lymphocytes | 3 | 2023 | 887 | 0.230 |
Why?
| | Patient Preference | 2 | 2026 | 226 | 0.220 |
Why?
| | Neurons | 4 | 2026 | 1668 | 0.220 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 76 | 0.220 |
Why?
| | Treatment Outcome | 10 | 2026 | 11821 | 0.220 |
Why?
| | Remyelination | 1 | 2025 | 15 | 0.220 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.220 |
Why?
| | Multigene Family | 1 | 2005 | 210 | 0.210 |
Why?
| | Decision Making | 2 | 2026 | 993 | 0.210 |
Why?
| | Immunoglobulin A | 1 | 2026 | 205 | 0.210 |
Why?
| | Retrospective Studies | 10 | 2025 | 17438 | 0.210 |
Why?
| | White Matter | 1 | 2026 | 169 | 0.200 |
Why?
| | Isometric Contraction | 1 | 2026 | 200 | 0.200 |
Why?
| | Central Nervous System | 1 | 2026 | 278 | 0.200 |
Why?
| | Atrophy | 2 | 2021 | 199 | 0.200 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 61 | 0.190 |
Why?
| | Neuroprotection | 1 | 2023 | 46 | 0.190 |
Why?
| | Diphosphonates | 1 | 2003 | 68 | 0.190 |
Why?
| | Bone Resorption | 1 | 2003 | 81 | 0.190 |
Why?
| | Alemtuzumab | 1 | 2023 | 15 | 0.190 |
Why?
| | Nitro Compounds | 1 | 2023 | 8 | 0.190 |
Why?
| | Myelin Sheath | 1 | 2025 | 166 | 0.190 |
Why?
| | Disease Progression | 7 | 2026 | 2867 | 0.180 |
Why?
| | Quality of Life | 5 | 2026 | 3200 | 0.180 |
Why?
| | Cellular Senescence | 1 | 2025 | 225 | 0.180 |
Why?
| | Thiazoles | 1 | 2023 | 139 | 0.180 |
Why?
| | Microglia | 1 | 2025 | 289 | 0.180 |
Why?
| | Double-Blind Method | 6 | 2026 | 2070 | 0.180 |
Why?
| | Gadolinium | 2 | 2022 | 78 | 0.180 |
Why?
| | Interoception | 1 | 2021 | 3 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2026 | 846 | 0.170 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 597 | 0.170 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 24 | 0.170 |
Why?
| | Drug Costs | 1 | 2023 | 116 | 0.170 |
Why?
| | Neuroblastoma | 1 | 2023 | 177 | 0.170 |
Why?
| | Stair Climbing | 1 | 2021 | 6 | 0.170 |
Why?
| | Crotonates | 3 | 2026 | 7 | 0.170 |
Why?
| | Inflammation | 1 | 2013 | 2919 | 0.170 |
Why?
| | Toluidines | 3 | 2026 | 10 | 0.170 |
Why?
| | Hydroxybutyrates | 3 | 2026 | 15 | 0.170 |
Why?
| | Resistance Training | 1 | 2024 | 186 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 902 | 0.160 |
Why?
| | Lymphopenia | 1 | 2020 | 62 | 0.160 |
Why?
| | Young Adult | 7 | 2026 | 14330 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 781 | 0.150 |
Why?
| | Hippocampus | 3 | 2002 | 989 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 156 | 0.150 |
Why?
| | Personality | 1 | 2021 | 132 | 0.150 |
Why?
| | Torso | 1 | 2020 | 36 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2021 | 161 | 0.150 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2002 | 108 | 0.150 |
Why?
| | Neutropenia | 1 | 2020 | 153 | 0.150 |
Why?
| | Nitriles | 3 | 2026 | 212 | 0.150 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 23 | 0.150 |
Why?
| | Muscle Strength | 2 | 2024 | 340 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 467 | 0.150 |
Why?
| | Disease Management | 1 | 2023 | 651 | 0.150 |
Why?
| | Receptors, Glutamate | 1 | 1999 | 27 | 0.140 |
Why?
| | Sodium Glutamate | 1 | 1999 | 12 | 0.140 |
Why?
| | Pelvis | 1 | 2020 | 129 | 0.140 |
Why?
| | Avoidance Learning | 1 | 1999 | 64 | 0.140 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 73 | 0.140 |
Why?
| | Nerve Net | 1 | 2021 | 286 | 0.140 |
Why?
| | Muscle Spasticity | 1 | 2018 | 63 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 266 | 0.130 |
Why?
| | Cognition | 1 | 2026 | 1292 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2021 | 509 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 63 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 356 | 0.130 |
Why?
| | Reaction Time | 1 | 1999 | 438 | 0.120 |
Why?
| | Interferon beta-1a | 1 | 2016 | 12 | 0.120 |
Why?
| | Gait | 1 | 2020 | 322 | 0.120 |
Why?
| | Psychomotor Performance | 1 | 2019 | 329 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 416 | 0.120 |
Why?
| | Postural Balance | 1 | 2019 | 249 | 0.120 |
Why?
| | CD40 Antigens | 1 | 2016 | 69 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5439 | 0.120 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1137 | 0.120 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 91 | 0.120 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 93 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 790 | 0.120 |
Why?
| | Patient Care Planning | 1 | 2017 | 170 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 117 | 0.120 |
Why?
| | Prospective Studies | 2 | 2025 | 8123 | 0.110 |
Why?
| | Movement | 3 | 2023 | 290 | 0.110 |
Why?
| | Contrast Media | 1 | 2018 | 493 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 955 | 0.110 |
Why?
| | Survival Analysis | 1 | 2018 | 1378 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 307 | 0.110 |
Why?
| | Postpartum Period | 1 | 2017 | 377 | 0.100 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.100 |
Why?
| | Melanoma | 1 | 2021 | 765 | 0.100 |
Why?
| | Proteomics | 3 | 2026 | 1203 | 0.100 |
Why?
| | Disability Evaluation | 4 | 2018 | 297 | 0.100 |
Why?
| | Pyridines | 1 | 2018 | 610 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2021 | 806 | 0.100 |
Why?
| | Patient Participation | 1 | 2017 | 457 | 0.100 |
Why?
| | Pain | 1 | 2018 | 790 | 0.090 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 300 | 0.090 |
Why?
| | Aged | 7 | 2026 | 26432 | 0.090 |
Why?
| | Rats | 5 | 2005 | 5586 | 0.090 |
Why?
| | Dopamine | 2 | 2005 | 295 | 0.090 |
Why?
| | Adolescent | 5 | 2026 | 22557 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 37 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 96 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 7109 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2017 | 1130 | 0.080 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 161 | 0.080 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 432 | 0.080 |
Why?
| | Health Personnel | 1 | 2017 | 754 | 0.080 |
Why?
| | Hypoxia | 1 | 2017 | 1211 | 0.070 |
Why?
| | Leukocytes | 1 | 2011 | 301 | 0.070 |
Why?
| | Lymphocytes | 1 | 2011 | 379 | 0.070 |
Why?
| | Animals | 8 | 2025 | 38107 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5899 | 0.070 |
Why?
| | Neoplasms | 1 | 2024 | 2954 | 0.070 |
Why?
| | Pregnancy | 2 | 2018 | 7230 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2013 | 3647 | 0.070 |
Why?
| | Spinal Cord | 2 | 2012 | 378 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 699 | 0.060 |
Why?
| | Biomechanical Phenomena | 2 | 2021 | 874 | 0.060 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 266 | 0.060 |
Why?
| | Microinjections | 3 | 2002 | 92 | 0.060 |
Why?
| | Incidental Findings | 1 | 2026 | 81 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 51 | 0.060 |
Why?
| | Glycosylation | 1 | 2026 | 177 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 157 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 369 | 0.060 |
Why?
| | Protein Aggregates | 1 | 2026 | 87 | 0.060 |
Why?
| | Chemokine CCL11 | 1 | 2025 | 25 | 0.060 |
Why?
| | Cohort Studies | 3 | 2026 | 6077 | 0.050 |
Why?
| | Organ Specificity | 1 | 2005 | 307 | 0.050 |
Why?
| | Pilot Projects | 2 | 2021 | 1888 | 0.050 |
Why?
| | Cytoplasm | 1 | 2005 | 253 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2026 | 284 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 155 | 0.050 |
Why?
| | Species Specificity | 1 | 2005 | 543 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10921 | 0.050 |
Why?
| | Electric Stimulation | 2 | 2021 | 273 | 0.050 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 25 | 0.050 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 72 | 0.050 |
Why?
| | Osteolysis | 1 | 2003 | 17 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1761 | 0.050 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 79 | 0.050 |
Why?
| | Electromyography | 1 | 2026 | 428 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 752 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2081 | 0.050 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 78 | 0.050 |
Why?
| | Depression | 2 | 2026 | 1575 | 0.050 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 2 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18297 | 0.050 |
Why?
| | Aging | 2 | 2025 | 1996 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2025 | 198 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 16 | 0.050 |
Why?
| | Arm | 1 | 2023 | 111 | 0.040 |
Why?
| | Histamine | 1 | 1982 | 52 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2005 | 584 | 0.040 |
Why?
| | Cell Division | 1 | 2003 | 736 | 0.040 |
Why?
| | Maze Learning | 1 | 2002 | 106 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1185 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 129 | 0.040 |
Why?
| | Base Sequence | 1 | 2005 | 2123 | 0.040 |
Why?
| | Behavior, Animal | 2 | 2002 | 531 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2024 | 507 | 0.040 |
Why?
| | Heart | 1 | 2005 | 626 | 0.040 |
Why?
| | MART-1 Antigen | 1 | 2021 | 9 | 0.040 |
Why?
| | Gray Matter | 1 | 2022 | 96 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2838 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 693 | 0.040 |
Why?
| | Research Report | 1 | 2021 | 89 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 417 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1105 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 68 | 0.040 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 233 | 0.040 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 206 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 326 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 344 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 1135 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 689 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 167 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 41 | 0.040 |
Why?
| | Indolizines | 1 | 2018 | 13 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 568 | 0.030 |
Why?
| | Motor Skills | 1 | 2019 | 103 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1792 | 0.030 |
Why?
| | Hand | 1 | 2019 | 157 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 83 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1271 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2019 | 149 | 0.030 |
Why?
| | Leg | 1 | 2019 | 246 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 646 | 0.030 |
Why?
| | Headache | 1 | 2018 | 150 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 465 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 50 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1488 | 0.030 |
Why?
| | Internet | 1 | 2021 | 660 | 0.030 |
Why?
| | Macrophages | 1 | 2025 | 1532 | 0.030 |
Why?
| | Knee Joint | 1 | 2021 | 453 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1864 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 224 | 0.030 |
Why?
| | Memory | 1 | 1999 | 298 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 220 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 496 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1982 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 174 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 415 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1763 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 3545 | 0.030 |
Why?
| | Risk | 1 | 2017 | 920 | 0.030 |
Why?
| | Pyrazoles | 1 | 2018 | 517 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2439 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 588 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 365 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 6034 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1036 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2936 | 0.020 |
Why?
| | Prognosis | 1 | 2022 | 4351 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1327 | 0.020 |
Why?
| | Genetic Markers | 1 | 2013 | 340 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2219 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1724 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2017 | 553 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 426 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 614 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6460 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 573 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1210 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 421 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8391 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2921 | 0.010 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 17 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 56 | 0.010 |
Why?
| | Mesencephalon | 1 | 2004 | 65 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 112 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 123 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 245 | 0.010 |
Why?
| | Grooming | 1 | 1982 | 9 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 190 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 29 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1982 | 316 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 181 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 229 | 0.010 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 122 | 0.010 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2002 | 119 | 0.010 |
Why?
| | Locomotion | 1 | 1982 | 102 | 0.010 |
Why?
| | Catheterization | 1 | 2002 | 179 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 165 | 0.010 |
Why?
| | United States | 1 | 2018 | 16136 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1041 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1177 | 0.010 |
Why?
| | Action Potentials | 1 | 2002 | 500 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 1463 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 614 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2502 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4118 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 3206 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|